An Open-Label Study of the Transition to Rivaroxaban From Low-Molecular Weight Heparin for Venous Thromboembolism Prophylaxis After Total Joint Replacement: The Safe Simple Transitions Study.
Phase of Trial: Phase III
Latest Information Update: 21 Mar 2017
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Therapeutic Use
- Sponsors Janssen Pharmaceuticals
- 21 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Apr 2010 New trial record